Drugs / MK-3120
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05906537 | Jul 2023 → Dec 2026 expected | cancer | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07232602 | Feb 2026 → Jul 2031 expected | urinary bladder cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07222488 | Dec 2025 → Feb 2029 expected | urinary bladder cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06818643 | Mar 2025 → Oct 2028 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05562830 | Nov 2022 → Feb 2029 expected | urothelial carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3120 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07222488 ↗ |
| Known as | SKB410 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05906537 ↗ |
| Route | Intravenous | “Administered as an IV infusion on Day 1, Day 15, and Day 29 of each 6 week cycle.” NCT05562830 ↗ |